Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without ...

By Arjan Singh Conferences and trade shows are great places to learn about your competitive environment, as most companies in the industry usually attend these events; this includes competitors, ...

The article discusses the risks of non-compliance with federal laws in sponsored genetic testing programs and offers insights from Morrison Foerster experts.

Trade secrets protect innovation by keeping that innovation secret. But trade secret protection is lost once the trade secret becomes known to the public. Biotechs should have a strategic plan for ...

Because of the unknowns around revenue streams, biotech valuation may appear to be more guesswork than science. However, common valuation methods can help account for some of the product-line ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based Newco, explain experts at Orrick.

Sponsors need to proactively identify and manage the risks involved with working with a CRO. This kind of oversight can help reduce the likelihood of negative consequences that could impact the ...

Chris Anzalone, CEO of Arrowhead Pharmaceuticals, discusses overcoming adversity while leading the company through challenging times.

Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI tools improve the probability of success and likelihood of drug approval.